5 results on '"LR-4"'
Search Results
2. Immunoinformatics Study: Multi-Epitope Based Vaccine Design from SARS-CoV-2 Spike Glycoprotein.
- Author
-
Umitaibatin, Ramadhita, Harisna, Azza Hanif, Jauhar, Muhammad Miftah, Syaifie, Putri Hawa, Arda, Adzani Gaisani, Nugroho, Dwi Wahyu, Ramadhan, Donny, Mardliyati, Etik, Shalannanda, Wervyan, and Anshori, Isa
- Subjects
COVID-19 ,SARS-CoV-2 ,MOLECULAR dynamics ,VACCINE effectiveness ,T cells - Abstract
The coronavirus disease 2019 outbreak has become a huge challenge in the human sector for the past two years. The coronavirus is capable of mutating at a higher rate than other viruses. Thus, an approach for creating an effective vaccine is still needed to induce antibodies against multiple variants with lower side effects. Currently, there is a lack of research on designing a multiepitope of the COVID-19 spike protein for the Indonesian population with comprehensive immunoinformatic analysis. Therefore, this study aimed to design a multiepitope-based vaccine for the Indonesian population using an immunoinformatic approach. This study was conducted using the SARS-CoV-2 spike glycoprotein sequences from Indonesia that were retrieved from the GISAID database. Three SARS-CoV-2 sequences, with IDs of EIJK-61453, UGM0002, and B.1.1.7 were selected. The CD8+ cytotoxic T-cell lymphocyte (CTL) epitope, CD4+ helper T lymphocyte (HTL) epitope, B-cell epitope, and IFN-γ production were predicted. After modeling the vaccines, molecular docking, molecular dynamics, in silico immune simulations, and plasmid vector design were performed. The designed vaccine is antigenic, non-allergenic, non-toxic, capable of inducing IFN-γ with a population reach of 86.29% in Indonesia, and has good stability during molecular dynamics and immune simulation. Hence, this vaccine model is recommended to be investigated for further study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Immunoinformatics Study: Multi-Epitope Based Vaccine Design from SARS-CoV-2 Spike Glycoprotein
- Author
-
Ramadhita Umitaibatin, Azza Hanif Harisna, Muhammad Miftah Jauhar, Putri Hawa Syaifie, Adzani Gaisani Arda, Dwi Wahyu Nugroho, Donny Ramadhan, Etik Mardliyati, Wervyan Shalannanda, and Isa Anshori
- Subjects
antigenic epitope ,epitope prediction ,spike glycoprotein ,TLR-3 ,LR-4 ,Medicine - Abstract
The coronavirus disease 2019 outbreak has become a huge challenge in the human sector for the past two years. The coronavirus is capable of mutating at a higher rate than other viruses. Thus, an approach for creating an effective vaccine is still needed to induce antibodies against multiple variants with lower side effects. Currently, there is a lack of research on designing a multiepitope of the COVID-19 spike protein for the Indonesian population with comprehensive immunoinformatic analysis. Therefore, this study aimed to design a multiepitope-based vaccine for the Indonesian population using an immunoinformatic approach. This study was conducted using the SARS-CoV-2 spike glycoprotein sequences from Indonesia that were retrieved from the GISAID database. Three SARS-CoV-2 sequences, with IDs of EIJK-61453, UGM0002, and B.1.1.7 were selected. The CD8+ cytotoxic T-cell lymphocyte (CTL) epitope, CD4+ helper T lymphocyte (HTL) epitope, B-cell epitope, and IFN-γ production were predicted. After modeling the vaccines, molecular docking, molecular dynamics, in silico immune simulations, and plasmid vector design were performed. The designed vaccine is antigenic, non-allergenic, non-toxic, capable of inducing IFN-γ with a population reach of 86.29% in Indonesia, and has good stability during molecular dynamics and immune simulation. Hence, this vaccine model is recommended to be investigated for further study.
- Published
- 2023
- Full Text
- View/download PDF
4. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up.
- Author
-
Agnello, Francesco, Albano, Domenico, Sparacia, Gianvincenzo, Micci, Giuseppe, Matranga, Domenica, Toia, Patrizia, La Grutta, Ludovico, Grassedonio, Emanuele, Lo Re, Giuseppe, Salvaggio, Giuseppe, Midiri, Massimo, and Galia, Massimo
- Subjects
- *
DIAMETER , *ARSENIC - Abstract
The aim of this study was to retrospectively analyze the outcome of LR-3 and LR-4 without arterial phase hyperenhancement (APHE), and identify which features could predict LR-5 progression on serial Gd-EOB-DTPA-enhanced MRI follow-up. Forty-nine cirrhotic patients with 55 LR-3 and 19 LR-4 without APHE were evaluated. Observations were classified as decreased, stable or increased in category at follow-up. Observation size and LI-RADS major and ancillary features were evaluated. Seventeen/fifty-five (31%) LR-3 and 8/19 (42%) LR-4 progressed to LR-5 at follow-up. Baseline LI-RADS major and ancillary features were not significantly different among LR-3 and LR-4. A diameter ≥ 10 mm significantly increased LR-5 progression risk of LR-3 (OR = 6.07; 95% CI: 0.12; 60.28]; P <.001). LR-4 with a diameter ≥ 10 mm more likely become LR-5 at follow-up (OR = 8.95; 95% CI: 0.73; 111.8; P =.083]). LR-3 and LR-4 without APHE were often downgraded or remained stable in category on Gd-EOB-DTPA-enhanced MRI follow-up. • Most LR-3 and LR-4 without APHE were downgraded or remained stable in category on Gd-EOB-DTPA-enhanced MRI follow-up. • Baseline major and ancillary Li-RADS features were not significantly different between observations that progressed from LR-3 and LR-4 to LR-5 and those that did not. • Diameter of at least one 10 mm increased the risk of LR-5 transformation of LR-3 and LR-4. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up
- Author
-
Massimo Midiri, Giuseppe Salvaggio, Gianvincenzo Sparacia, Ludovico La Grutta, Domenica Matranga, Emanuele Grassedonio, Francesco Agnello, Giuseppe Lo Re, Domenico Albano, Patrizia Toia, Giuseppe Micci, Massimo Galia, Agnello F., Albano D., Sparacia G., Micci G., Matranga D., Toia P., La Grutta L., Grassedonio E., Lo Re G., Salvaggio G., Midiri M., and Galia M.
- Subjects
Gadolinium DTPA ,Gd-EOB-DTPA-enhanced MRI ,LR-3 ,Carcinoma, Hepatocellular ,LR-4 ,business.industry ,Liver Neoplasms ,Gd-EOB-DTPA ,Contrast Media ,Magnetic Resonance Imaging ,030218 nuclear medicine & medical imaging ,Settore MED/01 - Statistica Medica ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medicine ,Humans ,LI-RADS ,Radiology, Nuclear Medicine and imaging ,Nuclear medicine ,business ,Settore MED/36 - Diagnostica Per Immagini E Radioterapia ,Arterial phase ,Follow-Up Studies ,Retrospective Studies - Abstract
Objective: The aim of this study was to retrospectively analyze the outcome of LR-3 and LR-4 without arterial phase hyperenhancement (APHE), and identify which features could predict LR-5 progression on serial Gd-EOB-DTPA-enhanced MRI follow-up. Methods: Forty-nine cirrhotic patients with 55 LR-3 and 19 LR-4 without APHE were evaluated. Observations were classified as decreased, stable or increased in category at follow-up. Observation size and LI-RADS major and ancillary features were evaluated. Results: Seventeen/fifty-five (31%) LR-3 and 8/19 (42%) LR-4 progressed to LR-5 at follow-up. Baseline LI-RADS major and ancillary features were not significantly different among LR-3 and LR-4. A diameter ≥ 10 mm significantly increased LR-5 progression risk of LR-3 (OR = 6.07; 95% CI: 0.12; 60.28]; P < .001). LR-4 with a diameter ≥ 10 mm more likely become LR-5 at follow-up (OR = 8.95; 95% CI: 0.73; 111.8; P = .083]). Conclusion: LR-3 and LR-4 without APHE were often downgraded or remained stable in category on Gd-EOB-DTPA-enhanced MRI follow-up.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.